Any idea what percentage of the float has been shorted? I am guessing the failure to cover number is quite high. If you would be so kind could you send me any pertinent links you have from the company so I can do some catching up. I am thinking of purchasing this in my daughters account since she is not of majority age so it will go into a trust. The growth potential versus loss may make an good addition to her portfolio. Thank you.
Well said... I would make the following change. “Phase 2 of a multi-national trial starts next week and all laboratory tests AND MULTIPLE PREVIOUS PHASE 2 HUMAN TRIALS FOR OTHER INDICATIONS show that it is HIGHLY LIKELY Brilacidin will show great efficacy in human patients.”
Newby’s might also want to know Brilacidin’s MOA. The Brilacidin particles basically stab the virus to death. This is the same way it defeated the bacteria which causes ABSSSI (Acute Bacterial Skin and Skin Structure Infections) in two separate Phase 2 human trials.